Urticaria associated with antigonadotropin-releasing hormone antibody in a female Kallman's syndrome patient being treated with long-term pulsatile gonadotropin-releasing hormone.
The administration of pulsatile gonadotropin-releasing hormone (GnRH) has received increasing attention as a method of inducing ovulation or initiating puberty. Few side effects have been reported, although urticarial allergic reactions have been reported in the male. An 18-year-old female with hypogonadotropic hypogonadism and anosmia due to lack of endogenous GnRH was treated for 230 days using subcutaneous GnRH in an attempt to induce physiologic puberty. Just before anticipated menarche, therapy was discontinued because of the appearance of an urticarial reaction at the injection site as well as at previous injection sites. The presence of immunoglobulin G (IgG) antibodies against GnRH were subsequently identified in the patient's serum. These results further confirm the potential for antibody production to this small natural peptide in the female not previously exposed to GnRH. Some practical considerations for this form of therapy are highlighted.
D000293:Adolescent; D000568:Amenorrhea / Q000188:drug therapy* / Q000276:immunology; D000917:Antibody Formation; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D010906:Pituitary Hormone-Releasing Hormones / Q000009:adverse effects*; D011628:Puberty, Delayed / Q000188:drug therapy* / Q000276:immunology; D014581:Urticaria / Q000139:chemically induced* / Q000276:immunology
D007074:Immunoglobulin G; D010906:Pituitary Hormone-Releasing Hormones